Yu et al. demonstrated that combining the USP7i compound with trastuzumab slows down tumor growth in patient-derived xenografts (PDX) from a patient with a positive human epidermal growth factor receptor 2 (HER2+). This evidence concerns the gene ERBB2 and neoplasm.